Rheumatology (Oxford, England) · 2026
Bacterial translocation and intestinal permeability in early axial spondyloarthritis association with 5-year outcomes: insights from the DESIR cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verhoeven Frank, Fakih Olivier, Hecquet Sophie, Tournadre Anne, Saas Philippe, Pais de Barros Jean-Paul, Bamoulid Jamal, Tournier Maude, Totoson Perle, Prati Clément, Demougeot Céline, Wendling Daniel
Аннотация
OBJECTIVES: To evaluate the association between initial serological markers of intestinal permeability (IP) and bacterial translocation (BT), and the development of extra-musculoskeletal manifestations (EMMs) and radiographic progression in axial spondyloarthritis (axSpA).
METHODS: Serum samples from axSpA patients included in the DESIR cohort with clinical data available at 5 years were analysed. Gut permeability was assessed by zonulin levels and BT was assessed by lipopolysaccharide (LPS)-derived 3-hydroxymyristate and phospholipid transferase protein (PLTP) levels. The associations of baseline serological markers with the presence of EMM and imaging SI scores were analysed both at baseline and as primary outcomes of disease progression after 5 years follow-up. Associations were tested using univariate and multivariate logistic regression analyses.
RESULTS: A total of 297 patients were included (mean age 31.5 ± 7.4 years; 48.5% female; 88.9% HLA-B27 positive). Baseline levels of 3-hydroxymyristate, PLTP activity and zonulin showed no association with the presence or incidence of EMM. Baseline zonulin levels were lower in patients with baseline radiographic sacroiliitis (88.1 vs 140.6 ng/ml, P < 0.001), though this was not confirmed in multivariate linear regression. PLTP activity was positively correlated with the baseline SPARCC SI joint score (β = 0.61, P = 0.02), and this association remained significant after adjusting for age, sex and CRP (β = 0.58, P = 0.03). Moreover, PLTP activity was significantly higher in patients with radiographic sacroiliitis progression (6.1 vs 5.2 nmol/h/ml, P = 0.02), an effect maintained after adjustment (β = 0.27, P = 0.02).
CONCLUSION: PLTP activity is a promising biomarker associated with SI joint inflammation and radiographic progression over 5 years in recent axSpA.
METHODS: Serum samples from axSpA patients included in the DESIR cohort with clinical data available at 5 years were analysed. Gut permeability was assessed by zonulin levels and BT was assessed by lipopolysaccharide (LPS)-derived 3-hydroxymyristate and phospholipid transferase protein (PLTP) levels. The associations of baseline serological markers with the presence of EMM and imaging SI scores were analysed both at baseline and as primary outcomes of disease progression after 5 years follow-up. Associations were tested using univariate and multivariate logistic regression analyses.
RESULTS: A total of 297 patients were included (mean age 31.5 ± 7.4 years; 48.5% female; 88.9% HLA-B27 positive). Baseline levels of 3-hydroxymyristate, PLTP activity and zonulin showed no association with the presence or incidence of EMM. Baseline zonulin levels were lower in patients with baseline radiographic sacroiliitis (88.1 vs 140.6 ng/ml, P < 0.001), though this was not confirmed in multivariate linear regression. PLTP activity was positively correlated with the baseline SPARCC SI joint score (β = 0.61, P = 0.02), and this association remained significant after adjusting for age, sex and CRP (β = 0.58, P = 0.03). Moreover, PLTP activity was significantly higher in patients with radiographic sacroiliitis progression (6.1 vs 5.2 nmol/h/ml, P = 0.02), an effect maintained after adjustment (β = 0.27, P = 0.02).
CONCLUSION: PLTP activity is a promising biomarker associated with SI joint inflammation and radiographic progression over 5 years in recent axSpA.